News Release - June 6, 2007

Phase III Study Evaluating Gilead's Viread(R) for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint

Source: Gilead Sciences

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.